"This past August, the FDA approved the first chimeric antigen receptor T cell (CAR-T) immunotherapy, Novartis’ Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). It uses specifically developed Cell Therapy Systems (CTS) Dynabeads technology, part of Thermo Fisher's CTS portfolio. The magnetic beads isolate, activate and expand T cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.
Recently, Kite Pharma received approval from the FDA for Yescarta, a CAR T therapy for the treatment of relapsed or refractory large B-cell lymphoma. Kite, headquartered in Santa Monica, CA, was recently acquired by Gilead for approximately $11.9 billion.
Cryoport, a provider of cold chain logistics for temperature-sensitive life sciences materials, is the logistics shipper for both of these products, which represent the first two commercialized CAR-T cell therapies now available for patients. Jerrell Shelton, Cryoport’s chief executive officer discusses the processes and technologies associated with supporting logistics for CAR-T therapies." Read full article in Contract Pharma>